Investor sentiment toward related affiliates improved following news that an anticancer drug developed by a domestic biotech company received product approval in the United States. According to overseas subsidiaries, the drug was approved as follow-up treatment for cholangiocarcinoma patients with specific genetic mutations. The company holding global development and commercialization rights is planning to launch the drug in the U.S. market. The market noted that product approval could lead to future sales and business expansion. While a significant number of related affiliates saw their stock prices rise, certain stocks declined due to profit-taking. With differing trends among stocks even on the same drug news, it's important to consider the business connectivity of each company and portfolio management strategies together.


In situations where expectations for new drug commercialization and profit-taking intersect, it's crucial to not only seek investment opportunities but also manage funding burdens efficiently. Especially for investors using margin trading or unsettled transactions, it is important to review capital management strategies that allow for more stable investment planning in anticipation of forced liquidation risk. Exploring financial services such as credit and unsettled trade refinancing—taking into account interest rates and repayment burdens—can help investors respond to market changes and establish a sound management strategy.


HISTOCKLOAN has maintained its number one position in the industry for 22 years, providing a wide range of stock funding products, including options with an annual interest rate in the 5% range. Investors can use it both to secure new investment funds and to refinance existing margin and unsettled trades at a lower cost, making HISTOCKLOAN a notable choice for those seeking efficient capital management while maintaining investment opportunities.

Diverging Stock Prices Amid New Drug Expectations... Reviewing Capital Management via Margin and Unsettled Trade Refinancing View original image

[Go to HISTOCKLOAN, the No. 1 in the industry: https://www.hisl.co.kr]


◆ HISTOCKLOAN, introducing an industry-low 5% annual rate for both additional investment funds and credit/refinance of unsettled balances!

HISTOCKLOAN has launched a securities-linked margin product available to all investors at an industry-low annual interest rate in the 5% range, allowing easy access to stock loans. Investors can use it for both stock purchases and real-time refinancing of unsettled and margin balances at brokerages, and can leverage up to 4 times their own capital, regardless of credit rating. It is also available to investors using alternative trading systems (NXT).


Investors interested in HISTOCKLOAN’s customized products can contact the customer service center (☎1566-5113) to receive convenient consultation with an expert at any time, 24 hours a day, regardless of whether they ultimately take out a loan.


○ New product with industry-low 5% annual rate launched

○ ETF trading available

○ Ranked No. 1 in market share for 22 consecutive years, and awarded Korea First Brand for 17 years in a row

○ Real-time repayment of unsettled and margin trades at brokerages

○ Accessible for Alternative Trading System (NXT) users

○ Reliable consultation quality guarantee system

* HISTOCKLOAN Consultation Center: 1566-5113

Go directly: https://www.hisl.co.kr


HLB, Daewoo Engineering & Construction, Hankem, Korea Circuit, Doosan



※ The above content is unrelated to the editorial direction of The Asia Business Daily, and all responsibility belongs to the information provider.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing